Although research in this area is still evolving, preclinical data suggest that combining specific PI3K inhibitors with existing anti-HER2 therapies may enhance their efficacy and help to avoid resistance in cases of PIK3CA-mutant HER2+ advanced breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.